Evidence map›Paper›PMID 33634023›Full record

ArticleFrontiers in oncology2020

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma.

Jingjing Ge, Cheng Li, Fengjun Xue, Shaopei Qi, Zhimeng Gao, Chunjiang Yu, Junping Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jingjing GeDepartment of Neuro-Oncology, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Cheng LiDepartment of Neuro-Oncology, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Fengjun XueDepartment of Neuro-Oncology, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Shaopei QiDepartment of Neuro-Oncology, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Zhimeng GaoDepartment of Neuro-Oncology, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Chunjiang YuDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Junping ZhangDepartment of Neuro-Oncology, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Beijing Sanbo Brain Hospital · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment for recurrent glioblastoma is poor, and there is a need for better therapies. Here we retrospectively assessed the efficacy and toxicity of temozolomide plus apatinib, an oral small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 in recurrent glioblastoma. MATERIALS AND

methodsA retrospective analysis of patients with recurrent glioblastoma who underwent apatinib plus temozolomide treatment was performed. Apatinib was given at 500 mg once daily. Temozolomide was administered at 200 mg/m

resultsFrom April 2016 to August 2019, thirty-one patients were identified. The objective response rate was 26.3%, and the disease control rate was 84.2%. The progression-free survival (PFS) at 6 months and overall survival (OS) at 12 months were 44.6 and 30.2%. The median PFS and OS were 4.9 and 8.2 months, respectively. Two patients achieved long PFS of 30.9 and 38.7+ months. The median survival time after progression of the patients with or without salvage bevacizumab was 5.1

conclusionApatinib plus temozolomide is an effective salvage regimen with manageable toxicities for recurrent glioblastoma and could not reduce the sensitivity to bevacizumab.

Indexed as

angiogenesis inhibitorsapatinibchemotherapyglioblastomatemozolomideVEGFR-2

Identifiers

PMID33634023
PMCPMC7901881
OpenAlexW3127878628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.